When troglitazone and Δ2-TG were tested for growth inhibition in twoprostate cancer cell lines: one cell line expressing high levels of PPARγ (PC-3) and one deficient of PPARγ expression (LNCaP), the LNCaP cells were moresensitive to troglitazone compared to PC-3 cells despite being deficient inPPARγ. The gene discussed is PPARG; the disease is cancer.